Find out how the release of Luxturna, Novartis/Spark Therapeutics’ new one-time gene therapy for inherited retinal dystrophy, heralds a new era for the company, as they intend to use the lessons learned from the launch to inform future gene therapy strategy. Janneke van der Kamp, the Global Head of Product and Portfolio Strategy for Novartis, sat down with Scrip to discuss the launch and its influence on the future pricing and reimbursement strategies likely to be adopted by the Swiss firm.
Luxturna Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
- Report
- 175 Pages
- Global
